Cargando…
Screening the Pathogen Box to Discover and Characterize New Cruzain and TbrCatL Inhibitors
Chagas disease and Human African Trypanosomiasis, caused by Trypanosoma cruzi and T. brucei, respectively, pose relevant health challenges throughout the world, placing 65 to 70 million people at risk each. Given the limited efficacy and severe side effects associated with current chemotherapy, new...
Autores principales: | do Valle Moreira, Thales, Martins, Luan Carvalho, Diniz, Lucas Abreu, Bernardes, Talita Cristina Diniz, de Oliveira, Renata Barbosa, Ferreira, Rafaela Salgado |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967275/ https://www.ncbi.nlm.nih.gov/pubmed/36839523 http://dx.doi.org/10.3390/pathogens12020251 |
Ejemplares similares
-
Computational approaches towards the discovery and optimisation of cruzain inhibitors
por: Santos, Viviane Corrêa, et al.
Publicado: (2022) -
Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors
por: Ferreira, Rafaela S., et al.
Publicado: (2010) -
Non-peptidic Cruzain Inhibitors with Trypanocidal Activity Discovered by Virtual Screening and In Vitro Assay
por: Wiggers, Helton J., et al.
Publicado: (2013) -
Multiparameter Optimization of Trypanocidal Cruzain Inhibitors With In Vivo Activity and Favorable Pharmacokinetics
por: Pauli, Ivani, et al.
Publicado: (2022) -
Computational Identification of Uncharacterized Cruzain Binding Sites
por: Durrant, Jacob D., et al.
Publicado: (2010)